ABBV
Price
$210.50
Change
+$2.57 (+1.24%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
367.3B
56 days until earnings call
BIIB
Price
$132.15
Change
-$0.50 (-0.38%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
19.45B
54 days until earnings call
Interact to see
Advertisement

ABBV vs BIIB

Header iconABBV vs BIIB Comparison
Open Charts ABBV vs BIIBBanner chart's image
ABBVIE
Price$210.50
Change+$2.57 (+1.24%)
Volume$29.73K
Capitalization367.3B
Biogen
Price$132.15
Change-$0.50 (-0.38%)
Volume$20.76K
Capitalization19.45B
ABBV vs BIIB Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. BIIB commentary
Aug 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and BIIB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 30, 2025
Stock price -- (ABBV: $207.92 vs. BIIB: $132.65)
Brand notoriety: ABBV and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 82% vs. BIIB: 113%
Market capitalization -- ABBV: $367.3B vs. BIIB: $19.45B
ABBV [@Pharmaceuticals: Major] is valued at $367.3B. BIIB’s [@Pharmaceuticals: Major] market capitalization is $19.45B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 2 FA rating(s) are green whileBIIB’s FA Score has 0 green FA rating(s).

  • ABBV’s FA Score: 2 green, 3 red.
  • BIIB’s FA Score: 0 green, 5 red.
According to our system of comparison, ABBV is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 4 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s).

  • ABBV’s TA Score: 4 bullish, 4 bearish.
  • BIIB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than BIIB.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -0.75% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -4.65% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +1.29%, and the average quarterly price growth was +11.90%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

BIIB is expected to report earnings on Oct 22, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.84% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($367B) has a higher market cap than BIIB($19.4B). ABBV has higher P/E ratio than BIIB: ABBV (99.01) vs BIIB (12.69). ABBV YTD gains are higher at: 20.231 vs. BIIB (-13.255). ABBV has higher annual earnings (EBITDA): 14.2B vs. BIIB (2.79B). ABBV has more cash in the bank: 6.47B vs. BIIB (2.76B). BIIB has less debt than ABBV: BIIB (6.6B) vs ABBV (70.5B). ABBV has higher revenues than BIIB: ABBV (58.3B) vs BIIB (10B).
ABBVBIIBABBV / BIIB
Capitalization367B19.4B1,892%
EBITDA14.2B2.79B508%
Gain YTD20.231-13.255-153%
P/E Ratio99.0112.69780%
Revenue58.3B10B583%
Total Cash6.47B2.76B234%
Total Debt70.5B6.6B1,069%
FUNDAMENTALS RATINGS
ABBV vs BIIB: Fundamental Ratings
ABBV
BIIB
OUTLOOK RATING
1..100
1816
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
11100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
2459
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
6585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABBV's Valuation (89) in the Pharmaceuticals Major industry is in the same range as BIIB (89) in the Biotechnology industry. This means that ABBV’s stock grew similarly to BIIB’s over the last 12 months.

ABBV's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.

ABBV's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that ABBV’s stock grew similarly to BIIB’s over the last 12 months.

ABBV's Price Growth Rating (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (59) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than BIIB’s over the last 12 months.

ABBV's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that ABBV’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVBIIB
RSI
ODDS (%)
Bearish Trend 2 days ago
42%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
67%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
70%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
57%
Advances
ODDS (%)
Bullish Trend 8 days ago
57%
Bullish Trend 8 days ago
53%
Declines
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
38%
Bearish Trend 2 days ago
69%
Aroon
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
57%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BULZ201.634.90
+2.49%
MicroSectors™ Slct FANG Inn 3X Lvgd ETNs
BEGS34.510.07
+0.22%
Rareview 2X Bull Cryptoccy & Prc Mtl ETF
JULW38.030.07
+0.19%
AllianzIM US Large Cap Buffer20 Jul ETF
BUL53.080.08
+0.14%
Pacer US Cash Cows Growth ETF
BEEZ33.680.01
+0.04%
Honeytree U.S. Equity ETF